Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis
Clinical Scorecard: Assessment of the Safety and Effectiveness of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer with EGFR Mutations Following Resistance to Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations
Key Mechanisms
Resistance to EGFR-tyrosine kinase inhibitors (TKIs) and potential efficacy of antibody-drug conjugates (ADCs)
Target Population
Adults with EGFR-mutant NSCLC after TKI failure
Care Setting
Oncology clinical trials
Key Highlights
Pooled objective response rate (ORR) for ADCs was 44.7%
TROP2-targeting ADCs showed a higher ORR (50.6%) compared to HER3-targeting ADCs (34.2%)
Sacituzumab tirumotecan demonstrated improved progression-free survival (PFS) and overall survival (OS) over chemotherapy
Patritumab deruxtecan improved PFS but OS data were immature
High between-study heterogeneity noted in ADC efficacy
Guideline-Based Recommendations
Diagnosis
Confirm EGFR mutations in NSCLC patients prior to treatment decisions
Management
Consider ADCs, particularly TROP2-targeting agents, for patients with EGFR-mutant NSCLC after TKI resistance
Monitoring & Follow-up
Monitor for efficacy and safety of ADC therapy in this population
Risks
Be aware of potential adverse effects associated with ADCs
Patient & Prescribing Data
Adults with EGFR-mutant NSCLC who have progressed on TKI therapy
Efficacy of ADCs varies by target antigen; TROP2-directed therapies show promising results
Clinical Best Practices
Utilize biomarker-guided patient selection for ADC therapy
Evaluate the specific ADC target when considering treatment options
In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market
